Current Hematologic Malignancy Reports
Overview
Current Hematologic Malignancy Reports is a scientific journal, published by Current Science since 2006 in English. The journal's country of origin is United States and its primary focus areas are oncology and hematology.
Details
Details
Abbr.
Curr Hematol Malig Rep
Publisher
Current Science
Start
2006
End
Continuing
Frequency
Quarterly
p-ISSN
1558-8211
e-ISSN
1558-822X
Country
United States
Language
English
Specialties
Oncology
Hematology
Hematology
Metrics
Metrics
h-index / Ranks: 8115
44
SJR / Ranks: 3818
998
CiteScore / Ranks: 3060
6.80
JIF / Ranks: 3624
2.9
Recent Articles
1.
Adrianzen-Herrera D, Strumlowska A
Curr Hematol Malig Rep
. 2025 Jan;
20(1):6.
PMID: 39821758
Purpose Of The Review: Myelodysplastic syndromes (MDS) are myeloid neoplasms characterized by high molecular and genomic heterogeneity. Accordingly, efforts in risk assessment and therapeutic intervention mostly target unique profiles that...
2.
Case K, Allen P
Curr Hematol Malig Rep
. 2025 Jan;
20(1):5.
PMID: 39800801
Purpose Of Review: Cutaneous T cell lymphomas (CTCLs) are comprised of a heterogenous group of non-Hodgkin lymphomas that can be difficult to treat and are often refractory to standard therapies....
3.
Faiz M, Riedemann M, Jutzi J, Mullally A
Curr Hematol Malig Rep
. 2025 Jan;
20(1):4.
PMID: 39775969
Purpose Of Review: More than a decade following the discovery of Calreticulin (CALR) mutations as drivers of myeloproliferative neoplasms (MPN), advances in the understanding of CALR-mutant MPN continue to emerge....
4.
Keesari P, Samuels D, Vegivinti C, Pulakurthi Y, Kudithi R, Dhar M, et al.
Curr Hematol Malig Rep
. 2025 Jan;
20(1):3.
PMID: 39754658
Purpose Of Review: Multiple myeloma is a chronic malignancy and with evolving treatment options, understanding the economic burden and cost-effectiveness of therapies is crucial for clinicians and researchers. Recent Findings:...
5.
Sarosiek S, Doughty C, Castillo J
Curr Hematol Malig Rep
. 2024 Dec;
20(1):2.
PMID: 39680359
Purpose Of Review: Peripheral neuropathy (PN) is more commonly seen in individuals with monoclonal gammopathies, especially in patients with an IgM monoclonal gammopathy or Waldenström macroglobulinemia. Recent Findings: There are...
6.
Islam N, Budvytyte L, Khera N, Hilal T
Curr Hematol Malig Rep
. 2024 Dec;
20(1):1.
PMID: 39630328
Purpose Of Review: Recent studies show that unresolved disparities hinder enrollment to clinical trials, equitable distribution of treatments, and impact the generalizability of trials, compromising health outcomes across different populations....
7.
Abedin S, Hamadani M
Curr Hematol Malig Rep
. 2024 Nov;
19(6):246-255.
PMID: 39520614
Purpose Of Review: Graft-versus-host disease (GVHD) is a serious complication after allogeneic HCT. Recently, several pivotal studies have been conducted demonstrating significant improvements in the management of GVHD. Here, we...
8.
Braunstein Z, Brammer J
Curr Hematol Malig Rep
. 2024 Oct;
19(6):276-284.
PMID: 39425756
Purpose Of Review: Given the poor outcomes for peripheral T-cell lymphomas (PTCL), stem cell transplant (SCT) remains an important therapeutic approach. Post-SCT relapse is common and maintenance therapy post-SCT is...
9.
Thaw K, Harrison C, Sriskandarajah P
Curr Hematol Malig Rep
. 2024 Oct;
19(6):264-275.
PMID: 39400853
Purpose Of Review: The landscape of myelofibrosis (MF) has changed since the discovery of the JAK2 V617F mutation and subsequent development of JAK inhibitors (JAKis). However, treatment with JAKis remain...
10.
Rajendra A, Gupta V
Curr Hematol Malig Rep
. 2024 Sep;
19(6):256-263.
PMID: 39240494
Purpose Of Review: Allogeneic hematopoietic cell transplantation is the only potentially curative treatment for myelofibrosis. This review discusses issues not well-covered by existing guidelines: timing of transplant, pre-transplant spleen management...